Browsing Clinical Studies by author "De Bono, Johann"
Now showing items 21-40 of 216
-
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Li, S; Fong, K-W; Gritsina, G; Zhang, A; Zhao, JC; et al. (AMER ASSOC CANCER RESEARCH, 2019-05-15)Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal disease. Transcriptome analysis of multiple prostate cancer models ... -
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; et al. (OXFORD UNIV PRESS, 2018-05-01)BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ... -
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; et al. (ELSEVIER SCIENCE INC, 2016-03-19)BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ... -
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; et al. (ELSEVIER, 2020-11-08)BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient ... -
Alternative splicing in prostate cancer.
Paschalis, A; Sharp, A; Welti, JC; Neeb, A; Raj, GV; et al. (NATURE PUBLISHING GROUP, 2018-11-01)Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain ... -
An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Thiery-Vuillemin, A; Fizazi, K; Sartor, O; Oudard, S; Bury, D; et al. (ELSEVIER, 2021-04-01)BACKGROUND: Men with metastatic castration-resistant prostate cancer (mCRPC) are living longer, therefore optimizing health-related quality of life (HRQL), as well as survival outcomes, is important for optimal patient ... -
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti, J; Rodrigues, DN; Sharp, A; Sun, S; Lorente, D; et al. (2016-10)Background The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide.Objective To develop a validated ... -
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti, J; Rodrigues, DN; Sharp, A; Sun, S; Lorente, D; et al. (ELSEVIER SCIENCE BV, 2016-10-01)BACKGROUND: The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide. OBJECTIVE: To develop a ... -
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
Crespo, M; van Dalum, G; Ferraldeschi, R; Zafeiriou, Z; Sideris, S; et al. (NATURE PUBLISHING GROUP, 2015-03-31)BACKGROUND: Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-based ... -
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp, A; Coleman, I; Yuan, W; Sprenger, C; Dolling, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2019-01-02)BACKGROUND: Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant ... -
Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.
Yin, Y; Li, R; Xu, K; Ding, S; Li, J; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-15)In prostate cancer, androgen deprivation therapy (ADT) enhances the cytotoxic effects of radiotherapy. This effect is associated with weakening of the DNA damage response (DDR) normally supported by the androgen receptor. ... -
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
Fletcher, CE; Sulpice, E; Combe, S; Shibakawa, A; Leach, DA; et al. (SPRINGERNATURE, 2019-07-11)Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, ... -
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono, JS; Chowdhury, S; Feyerabend, S; Elliott, T; Grande, E; et al. (ELSEVIER, 2018-07-01)BACKGROUND: Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between ... -
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
Roulstone, V; Mansfield, D; Harris, RJ; Twigger, K; White, C; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to ... -
Application of Liquid Biopsies in Cancer Targeted Therapy.
Sumanasuriya, S; Lambros, MB; de Bono, JS (WILEY, 2017-11-01)As a growing body of evidence demonstrates intertumoral and intratumoral heterogeneity and clonal evolution, both during carcinogenesis and also throughout treatment resulting in acquired drug resistance, the utility of ... -
AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.
Sowalsky, AG; Sharp, A; Trostel, SY; de Bono, JS; Plymate, SR (Elsevier BV, 2021-01-01) -
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
Armstrong, AJ; Al-Adhami, M; Lin, P; Parli, T; Sugg, J; et al. (AMER MEDICAL ASSOC, 2020-02-01)IMPORTANCE: For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic ... -
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.
Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; et al. (CIG MEDIA GROUP, LP, 2018-12-01)BACKGROUND: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM ... -
Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.
Maxwell, PJ; McKechnie, M; Armstrong, CW; Manley, JM; Ong, CW; et al. (AMER ASSOC CANCER RESEARCH, 2022-06-03)UNLABELLED: Inhibiting androgen signaling using androgen signaling inhibitors (ASI) remains the primary treatment for castrate-resistant prostate cancer. Acquired resistance to androgen receptor (AR)-targeted therapy ... -
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit, R; Wülfing, C; Castellano, D; Kramer, G; Eymard, J-C; et al. (ELSEVIER, 2021-08-24)BACKGROUND: There is growing evidence that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC). In the CARD ...